Interpreting GPS Results

Predict both clinical risk and tumor aggressiveness

Oncotype DX GPS is proven to be an independent predictor of:both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3 and 3+4^1-3.

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report.

See sample reports

For patients with:

• Very low NCCN risk and a GPS of 12
• Low NCCN risk and a GPS of 21
• Low NCCN risk and a GPS of 35

Getting your results

More than 90% of Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Genomic Health Laboratory. You can access the results through the online physician portal or receive the report by fax.

Report Highlights
Compare Report Results

Start Report Guide

Overall Risk

How does the overall clinical picture look?
By combining the Oncotype DX Genomic Prostate Score® (GPS) result with clinical features, the report provides clear risk stratification.

Prognosis*

What do long-term outcomes look like?
The Oncotype DX Genomic Prostate Score® has been prospectively validated to independently predict 10-year clinical risk of prostate cancer death and metastasis.

*From the KPNC clinical validation study, in which all patients received radical prostatectomy.

Tumor aggressiveness*

How aggressive is the underlying biology?
This single number is the most immediate and clinically actionable endpoint, predicting the patient's likelihood of adverse pathology (Gleason ≥ 4+3 and/or pT3+).

*From the UCSF and CPDR clinical validation studies.

Clinical utility

In this example, the patient's clinical features are consistent with NCCN Low Risk. Utilization of the GPS Test™ enables reclassification to NCCN Very Low Risk.

Start Report Guide

GPS distribution*

How does your patient's GPS result compare to his pre-test risk group?
Helps to personalize your conversations for shared decision-making about treatment options.

*From the KPNC, UCSF and CPDR clinical validation studies.

Pathology endpoints*

What is the risk for disease progression?
Get your patient's individualized risks for high grade disease and non-organ-confined disease.

*From a meta-analysis of the UCSF and CPDR clinical validation studies..

Page 1 2

Download PDF

Start Report Guide

Very Low Risk*

In this example, the patient's pre-test NCCN  risk was Low. GPS testing enabled reclassification to Very Low Risk, providing strong support for a conversation about Active Surveillance.

*National Comprehensive Cancer Network® clinical practice guidelines for prostate cancer.

Start Report Guide

Low Risk*

In this case, GPS testing confirmed a pre-test Low Risk result, potentially reinforcing confidence in Active Surveillance.

*National Comprehensive Cancer Network® clinical practice guidelines for prostate cancer.

Start Report Guide

Favorable Intermediate Risk*

In this final example, the GPS result reclassified the patient from Low to Favorable Intermediate Risk. Active Surveillance may still be an option after careful consideration of adverse pathology and patient preferences.

*National Comprehensive Cancer Network® clinical practice guidelines for prostate cancer.

Page 1 2 3

Download PDF